ClinicalTrials.gg

Program

gedatolisib

Also written as “PF-05212384”, “Gedatolisib” and “Arm A: Gedatolisib + Palbociclib + Fulvestrant”.

Its studies are mostly in Breast Neoplasms · Colorectal Neoplasms · Prostatic Neoplasms, Castration-Resistant · Endometrial Neoplasms · Neoplasms, led by 2 companies.

Furthest: phase 3, since Aug 17, 20119 company-led studies, 3 open or runningNext primary completion: Jan 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer50 open or runningphase 2since Aug 17, 2011Jul 14, 2009none ahead
Celcuity43 open or runningphase 3since Aug 12, 2022Feb 10, 2016Jan 2028phase 2 · NCT06190899

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 14, 2009First study: phase 1 study in NeoplasmsNew to PfizerPfizer · NCT00940498 · 78 enrolled · United States, Spain, United Kingdom
  2. Aug 17, 2011Phase 2 study in Endometrial NeoplasmsPfizer · NCT01420081 · 67 enrolled · United States, Australia, Canada and more
  3. Aug 15, 20132 phase 2 studies in Colorectal NeoplasmsPfizer · NCT01925274, NCT01937715
  4. May 13, 2014Phase 1 study in HealthyPfizer · NCT02142920 · 6 enrolled · United Kingdom
  5. Feb 10, 2016Celcuity's first study: phase 1 study in Breast NeoplasmsNew to CelcuityCelcuity · NCT02684032 · 141 enrolled · United States
  6. Aug 12, 2022Phase 3 study in Breast NeoplasmsCelcuity · NCT05501886 · 701 enrolled · United States, Argentina, Australia and more
  7. Dec 13, 2023Phase 2 study in Genital Diseases, MaleCelcuity · NCT06190899 · 54 planned · United States, France, Spain and more
  8. Dec 24, 2024Phase 3 study in Breast NeoplasmsCelcuity · NCT06757634 · 1,180 planned · United States, Argentina, Australia and more

Ahead

  1. Jan 2028Primary completion: phase 2 study in Genital Diseases, MaleCelcuity · NCT06190899
  2. Mar 31, 2029Primary completion: phase 3 study in Breast NeoplasmsCelcuity · NCT06757634

TargetBeta

“An agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway, ”NCIt, by rule
“Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor”ChEMBL 37, by rule

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06757634Breast Neoplasms · United States, Argentina, Australia and more3RecruitingCelcuityMar 31, 20291,180
NCT06190899Genital Diseases, Male · United States, France, Spain and more2RecruitingCelcuityJan 202854
NCT05501886Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingCelcuityJun 30, 2026701
NCT02684032Breast Neoplasms · United States1CompletedCelcuityJan 19, 2022141
NCT02142920Healthy · United Kingdom1CompletedPfizerAug 20146
NCT01937715Colorectal Neoplasms · United States, Canada, Spain2TerminatedPfizerAug 201518
NCT01925274Colorectal Neoplasms · United States, Japan, Korea, Republic of and more2TerminatedPfizerApr 6, 201619
NCT01420081Endometrial Neoplasms · United States, Australia, Canada and more2TerminatedPfizerApr 30, 201467
NCT00940498Neoplasms · United States, Spain, United Kingdom1CompletedPfizerAug 201178

How it is read

Names in the registry

  • “PF-05212384”, 6 entries
  • “Gedatolisib”, 3 entries
  • “Arm A: Gedatolisib + Palbociclib + Fulvestrant”, 1 entry
  • “Arm C: Gedatolisib + Palbociclib + Letrozole”, 1 entry
  • “PF-05212384 (also known as PKI-587)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.